



## TWEETORIAL REFERENCES

#Diagnosing and Treating #Alzheimer Disease (AD) During the Early Stage

June 2, 2022

[VIEW ON TWITTER]

### Tweet #7

About Alzheimer's and Dementia: What Is Dementia? *Alzheimer's Disease International*. Accessed June 1, 2022. <https://www.alzint.org/about/>

Lang L, Clifford A, Wei L, et al. Prevalence and determinants of undetected dementia in the community: a systematic literature review and a meta-analysis. *BMJ Open* 2017;7:e011146. <https://doi.org/10.1136/bmjopen-2016-011146>

Atri A. The Alzheimer's disease clinical spectrum: diagnosis and management. *Med Clin North Am*. 2019;103(2):263-293. <https://doi.org/10.1016/j.mcna.2018.10.009>

### Tweet #8

Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):257-262. <https://doi.org/10.1016/j.jalz.2011.03.004>

Alzheimer's Association. 2020 Alzheimer's disease facts and figures. *Alzheimer's Dement*. 2020;16:391-460. <https://doi.org/10.1002/alz.12068>

### Tweet #9

Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):257-262. <https://doi.org/10.1016/j.jalz.2011.03.004>

### Tweet #10

Counts SE, Ikonomic MD, Mercado N, Vega IE, Mufson EJ. Biomarkers for the early detection and progression of Alzheimer's disease. *Neurotherapeutics*. 2017;14(1):35-53. <https://doi.org/10.1007/s13311-016-0481-z>

### Tweet #11

Counts SE, Ikonomic MD, Mercado N, Vega IE, Mufson EJ. Biomarkers for the early detection and progression of Alzheimer's disease. *Neurotherapeutics*. 2017;14(1):35-53. <https://doi.org/10.1007/s13311-016-0481-z>



#### **Tweet #12**

Atri A. The Alzheimer's disease clinical spectrum: diagnosis and management. *Med Clin North Am.* 2019;103(2):263-293. <https://doi.org/10.1016/j.mcna.2018.10.009>

#### **Tweet #13**

Birks J. Cholinesterase inhibitors for Alzheimer's disease. *Cochrane Database Syst Rev.* 2006;2006(1):CD005593. <https://doi.org/10.1002/14651858.CD005593>

#### **Tweet #14**

Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. *PLoS One.* 2015;10(4):e0123289. <https://doi.org/10.1371/journal.pone.0123289>

#### **Tweet #15**

Dou KX, Tan MS, Tan CC, et al. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials. *Alzheimers Res Ther.* 2018;10(1):126. <https://doi.org/10.1186/s13195-018-0457-9>

#### **Tweet #16**

Haddad HW, Malone GW, Comardelle NJ, Degueure AE, Kaye AM, Kaye AD. Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer's disease: a comprehensive review. *Health Psychology Research.* 2022;10(1). <https://doi.org/10.52965/001c.31925>

#### **Tweet #17**

Haddad HW, Malone GW, Comardelle NJ, Degueure AE, Kaye AM, Kaye AD. Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer's disease: a comprehensive review. *Health Psychology Research.* 2022;10(1). <https://doi.org/10.52965/001c.31925>

Esang M, Gupta M. Aducanumab as a novel treatment for Alzheimer's disease: a decade of hope, controversies, and the future. *Cureus.* 2021;13(8):e17591. Published 2021 Aug 31. <https://doi.org/10.7759/cureus.17591>

#### **Tweet #18**

Atri A. The Alzheimer's disease clinical spectrum: diagnosis and management. *Med Clin North Am.* 2019;103(2):263-293. <https://doi.org/10.1016/j.mcna.2018.10.009>



## GLOSSARY

AD	Alzheimer disease
A $\beta$ <sub>40</sub>	amyloid beta 40
A $\beta$ <sub>42</sub>	amyloid beta 42
b/f	before
ChEI	Cholinesterase inhibitors
cog	cognitive
CSF	cerebrospinal fluid
DMT	disease-modifying treatment
dx	diagnosis
FDG	fluorodeoxyglucose
fxnl	functional
Glu E	glutamate
incl	including
mAb	monoclonal antibody
MCI	mild cognitive impairment
MM	million
Neuropsych	neuropsychiatric
NMDA	N-methyl-D-aspartate
PET	positron emission tomography
P-tau	phosphorylated tau
QOL	quality of life
T-tau	total tau
tx	treatment
w/	with
pts	patients